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Abstract
The question of whether the human brain is an anatomical site of persistent HIV-1 infection during suppressive
antiretroviral therapy (ART) is critical, but remains unanswered. The presence of virus in the brains of HIV patients
whose viral load is effectively suppressed would demonstrate not only the potential for CNS to act as an anatomical
HIV reservoir, but also the urgent need to understand the factors contributing to persistent HIV behind the blood-
brain barrier. Here, we investigated for the first time the presence of cells harboring HIV DNA and RNA in the
brains from subjects with undetectable plasma viral load and sustained viral suppression, as identified by the
National NeuroAIDS Tissue Consortium. Using new, highly sensitive in situ hybridization techniques, RNAscope
and DNAscope, in combination with immunohistochemistry, we were able to detect HIV-1 in the brains of all virally
suppressed cases and found that brain macrophages and microglia, but not astrocytes, were the cells harboring HIV
DNA in the brain. This study demonstrated that HIV reservoirs persist in brain macrophages/microglia during
suppressive ART, which cure/treatment strategies will need to focus on targeting.
Keywords Antiretroviral therapy . Brain . HIV-1 . HIV-associated neurocognitive disorders . Macrophage . Reservoir
Introduction
The combination antiretroviral therapy (ART) has converted a
life-threatening human immunodeficiency virus (HIV) infec-
tion into a chronic disease. Nevertheless, life-long treatment is
required for those with this debilitating Bincurable^ disease.
While much effort has been focused on better understanding
the nature of HIV cellular latent reservoir in peripheral
blood cells and lymphoid tissues, non-lymphoid tissues
including brain have not been rigorously investigated.
Furthermore, despite the widespread use of ART, HIV-
associated neurocognitive disorders (HAND) remain surpris-
ingly common (Masliah et al. 2000; Sacktor et al. 2002;
McArthur et al. 2003; Becker et al. 2011; Harezlak et al.
2011). Even in individuals on successful HAARTwith unde-
tectable plasma viral load, HAND is still observed (Baeuerle
et al. 2005; Simioni et al. 2010; Bingham et al. 2011; Cysique
and Brew 2011). The basis of HAND in virally suppressed
individuals is unclear, and one possibility is that a cryptic HIV
replication in the brain may occur during suppressive
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antiretroviral therapy (ART); however, it remains to be tested
whether the human brain is an anatomical site of persistent
HIV-1 infection and/or ongoing low-level replication during
suppressive ART. Moreover, the cell types in brain that per-
sistently harbor HIV DNA and RNA in HIV patients on sup-
pressive ART with undetectable viral load in blood and cere-
brospinal fluid (CSF) are not established. Studies on HIV
reservoirs in the brain have been largely hampered by the
scarcity of autopsy brain tissue from HIV-infected individuals
who had been on ART and achieved viral suppression for
extended periods before their HIV-unrelated deaths.
Furthermore, such studies have also been hampered by the
lack of sensitive technologies for detecting the presence of
low-copy viral RNA (vRNA) and DNA (vDNA) in specific
cell types.
The National NeuroAIDS Tissue Consortium (NNTC)
identified a limited number of cases on ART with well-docu-
mented, sustained control of HIV-1 (BVirally Suppressed
Cases^). Exploiting this unique cohort, we used highly spe-
cific in situ hybridization (ISH) with single-copy sensitivity
(RNAscope and DNAscope) to detect and quantify HIV-1
vRNA and vDNA in the brain and determined the cell types
harboring vRNA and vDNA.Wewere able to detect persistent
HIV-1 DNA in the brains of all 16 virally suppressed cases. In
addition, we found that macrophages, including CD206+
perivascular macrophages (PVM) and some CD68+ mi-
croglia, harbored vDNA. Interestingly, no evidence for
infection of astrocytes was indicated by absence of
vDNA in astrocytes. Of note, we found, in some indi-
viduals (6/16) on suppressive ART with undetectable
viral loads in blood and CSF, the presence of isolated
focal vRNA in the brain. Together, these findings sug-
gest that macrophages and microglia are the HIV cellular
latent reservoir in brain, and that cure/treatment strategies are
needed to focus on targeting the macrophage/microglial viral
reservoir in the brain.
Materials and Methods
Study Subjects
The cases for this study were selected from over 900 human
autopsied brain specimens in the NNTC. The following 4
groups and a total of 29 cases were examined (Table 1):
Group 1 (N = 6) – HIV-1 uninfected subjects with minimal
non-diagnostic abnormalities at autopsy (HIV-); Group 2
(N = 7) – HIV-1-infected subjects with encephalitis (HIVE);
Group 3 (N = 8) – HIV-1-infected, virally suppressed subjects
with HAND (HAND); Group 4 (N = 8) – HIV-1-infected, vi-
rally suppressed subjects with no functional impairment (No
HAND). The further selection criteria for Groups 3 and 4 were
as follows:
Group 3: includes only HIVE-negative, suppressed cases
with probable/possible mild neurocognitive disorder or
HIV-associated dementia at last pre-mortem visit, but ex-
cludes hemorrhage dura/leptomeninges and bacterial pa-
renchymal infection at autopsy.
Group 4: includes only HIVE negative, suppressed cases
with normal or asymptomatic neurocognitive impairment
neurocognitive diagnosis at last pre-mortem visit, but ex-
clude hemorrhage dura/leptomeninges and bacterial pa-
renchymal infection at autopsy.
There were only 11 cases available for group 3 and 12
available for group 4. The NNTC sites randomly assigned 8
to each group. Groups 1 and 2 were matched as best as pos-
sible with respect to age, sex, and race; there was no statisti-
cally significant difference in demographic parameters
(Supplementary Table 1). Postmortem intervals were all under
48 h. Please visit the NNTC website (https://nntc.org/cohorts/
virally-suppressed-cases) for more information. Users can
search for a case by using a PRJID in Table 1.
Neuropsychological Assessment
All virally suppressed subjects received a 2-to-3-h battery of
neuropsychological (NP) tests. The tests are fully described
elsewhere (Fischer-Smith et al. 2001; Woods et al. 2004), and
also listed on the NNTC website. The NP battery in-
cluded tests of premorbid functioning, speed of informa-
tion processing, attention/working memory, verbal fluen-
cy, learning and memory, abstraction/executive function-
ing, motor skills, and assessments of everyday function-
ing and mood. Raw test scores were converted to age
and demographically corrected T scores, which were
then used to compute a deficit score that ranged from
0 (T score > 39, no impairments) to 5 (T score < 20,
severe impairment). Average deficit scores are computed
to yield an overall level of NP performance [global
deficit score (GDS)] (Blackstone et al. 2012). A diag-
nosis of HAND at the final pre-mortem visits was made
by American Academy of Neurology criteria that were
modified by the Frascati recommendations (Janssen et al.
1991; Antinori et al. 2007).
HIV vDNA and vRNA Detection Using DNAscope
and RNAscope ISH
HIV DNA and RNA in brain tissues were detected in
situ using sense and antisense probes from the
RNAscope® ISH probe-V-HIV1-clade B (Cat# 416111,
Advanced Cell Diagnostics) and RNAscope® 2.5 HD
assay-Red (Advanced Cell Diagnostics) for color devel-
opment, respectively. The RNAscope® negative control
probe-DapB (Cat# 310043, Advanced Cell Diagnostics)
was used as negative control. The DNAscope and
RNAscope ISH was conducted according to our previ-
ously reported protocol (Yuan et al. 2017). The tissue
sections, after RNAscope ISH or DNAscope ISH was
performed, were digitized with Aperio CS2 Scanscope.
For quantitative image analysis of vRNA- or vDNA-
positive cells, a positive pixel count algorithm in
Aperio’s Spectrum Plus analysis program (version 9.1;
Aperio ePathology Solutions) was used as we previously
reported (Wang et al. 2014).
Table 1 Patient characteristics
ProjID Category PMI Age at
death
Sex R Risk CD4 Plasma vl CSF vl Brain pathology Global deficit
score
01965 Uninfected 11 63 F W – – – – Abn-unspecified –
02711 Uninfected 29.7 54 M B – – – – normal –
02105 Uninfected 21.27 51 M H – – – – normal –
01640 Uninfected 19 63 M H – – – – normal –
01902 Uninfected 18.5 21 M H – – – – normal –
01923 Uninfected 6.5 61 M H – – – – Abn-Focal Infarct –
00039 HIVE 8 46 M W Hom-sx 15 167,143 11,908 HIVE 4.5
00284 HIVE 4 36 M H Hom-sx 16 195,269 – HIVE –
00488 HIVE 5.5 42 M W Hom-sx 99 6940 750,000 HIVE, MGNE –
01555 HIVE 48 47 M W Hom-sx 9 210,000 – HIVE –
01580 HIVE 4 50 M H IVDU 1 58,419 – HIVE –
01598 HIVE 27 45 F B IVDU 6 – – HIVE –
02390 HIVE 17 63 F B Het-sx 25 730,085 – HIVE –
01374 Virally Supressed
with HAND
22.5 54 M W Hom-sx 491 85 50 minimal 1.79
02398 Virally Supressed
with HANDI
4.5 64 M B Hom-sx 1043 40 na Leukoencephalopathy –
00630 Virally Supressed
with HAND
18.5 61 M B Het-sx, IVDU 271 50 50 Abn-unspecified 0.57
00699 Virally Supressed
with HAND










8.5 69 M W Hom-sx 355 20 60 ischemic 2.62
00006 Virally Supressed
with HAND
11.5 62 F B Het-sx 392 50 50 ischemic 0.15
00009 Virally Supressed
with HAND
11 50 F W Het-sx, IVDU 791 50 50 Abn-unspecified 0.6
02104 Virally Suppressed
no HAND
6 47 M H Hom-sx 61 48 – Abn-Focal Infarct 0.36
01495 Virally Suppressed
no HAND
7 39 M B Het-sx 112 40 – ischemic 0.21
00697 Virally Suppressed
no HAND
21 66 M W Hom-sx 798 50 – Abn-Focal Infarct 1.21
00522 Virally Suppressed
no HAND
24 66 M W Hom-sx 465 50 50 normal 0.07
00658 Virally Suppressed
no HAND
6 52 M W Hom-sx 78 50 50 normal 0
00719 Virally Suppressed
no HAND
20 44 M B IVDU 219 50 50 ischemic 0.86
01878 Virally Suppressed
no HAND
8.5 63 M W Hom-sx 133 50 50 ischemic 1.79
02087 Virally Suppressed
no HAND
14.5 51 M W Hom-sx 223 50 139 Abn - ChronicHTN 0.77
Determining the Cell Types of vRNA+ and vDNA+ Cells
Using RNAscope/DNAscope ISH in Combination
with Immunohistochemistry
The tissue sections of vRNA- or vDNA-positive tissue sec-
tions post ISH were digitized with Aperio CS2 Scanscope,
and then the coverslips of these tissue sections were removed
by soaking tissue slides in xylene overnight. The tissue sec-
tions were rehydrated for immunohistochemistry (IHC) con-
ducted as we reported (Li et al. 2009). Briefly, mouse-anti-
human CD68 monoclonal antibody (KP1, 1:200, Leica),
mouse-anti-human CD206 monoclonal antibody (5C11,
1:500, Abnova), or mouse-anti-GFAP monoclonal antibody
(ASTRO6, 1:100, Thermo Scientific) was used as the primary
antibody. Mouse IgG isotype control antibody was used as
negative control. EnVision anti-mouse HRP polymer kit
(Cat#: K400111–2, Agilent Dako) and substrate diaminoben-
zidine (DAB) were used to visualize antibody staining signals
as brown. After counterstained with hematoxylin, tissue sec-
tions were digitized with Aperio CS2 Scanscope and were
analyzed using Aperio’s Spectrum Plus analysis program (ver-
sion 9.1; Aperio ePathology Solutions) to separate into single
channels of vRNA, vDNA, or antibody staining signals. The
tissue sections on slides after combined DNAscope ISH with
IHC were also reviewed with Olympus Cell-Sens software
(1.18) after images were captured with DP72 CCD camera
at 60×/1.25 Oil Iris using Olympus microscope. To further
determine whether astrocytes support HIV productive infec-
tion, fluorescent RNAscope ISH was combined with immu-
nofluorescent staining of GFAP. Donkey anti-mouse IgG con-
jugated with Alexa Fluor 647 (Cat#: A-31571, Thermo Fisher
Scientific) was used as a secondary antibody and cell nuclei
were counterstained with DAPI. A Nikon A1R-TiE live cell
imaging confocal system was used to visualize and capture
images of stained samples.
SAMHD1 IHC
IHC for SAMHD1 was done on human brain tissues as we
previously reported (Lindgren et al. 2018)
Statistical Analysis
Descriptive statistics of the cohort data were presented
as mean (standard deviation) for continuous variables
and frequency (percent) for the categorical variables
(Supplementary Table 1). Comparisons of the HIV-infected
groups (G2, G3, and G4) within and across each of the three
brain regions with respect to HIV vDNAwere assessed using
a two-way ANOVA. Interaction effect between HIV-infected
groups and the brain areas was systematically considered and
retained based on its significance. Tukey pairwise multiple
comparison was used for the post hoc-analysis. Finally,
regression and Pearson correlation analyses were used to ex-
amine the relationship between HIV vDNA+ cells with
GDS and SAMHD1+ cells in specific brain regions.
All statistical analyses were performed using SAS ver-
sion 9.4 (SAS Institute, Inc., Cary, NC) and assessed
with a statistical significance level of alpha = 0.05.
Results
We set out to determine whether brain harbors HIV vDNA or
vRNA or both in the HIV-1-infected aviremic individuals who
were on suppressive ART, as well as what type of cells harbor
vDNA in those subjects. The NNTC identified 44 (now 56)
cases of HIV-infected aviremic subjects who were on suppres-
siveARTand donated the tissues including the brain. From this
rare resource we obtained 16 such cases with available cogni-
tive characterization to further stratify by HAND status (8 with
HAND and 8 with no HAND). In addition, we included HIV-
infected viremic individuals with encephalitis (HIVE group;
n = 7) and HIV-1 uninfected individuals as controls (Table 1).
We studied 3 brain regions, frontal white matter (FWM),
basal ganglia (BG) and corpus callosum (CC), of individuals
in all four above-described groups. We used RNAscope and
DNAscope ISH to detect vRNA and vDNA, respectively.
Fig. 1 Representative image of HIV vDNA+ cells detected in the brain
tissues of HIV infected aviremic individuals on suppressive ART. HIV
vDNA-positive cells (a discreet red dot in a nucleus, red circle; virally
suppressed subject 00009, FWM) were detected using sense probes from
the RNAscope® ISH probe-V-HIV1-clade B and RNAscope® 2.5 HD
assay-Red as a substrate (Advanced Cell Diagnostics). Cell nuclei were
counterstained with hematoxylin
We first examined HIV-1 DNA in all three brain regions
using DNAscope ISH. HIV vDNA signals (red puncta) were
consistently detected in all individuals from the three HIV-
infected groups including those who were virally suppressed
(Fig. 1).We then quantified the frequency of vDNA+ nuclei in
the entire section normalized with the total number of
hematoxylin-counterstained nuclei. HIV vDNA+ cells were
found in all three brain regions. A two-way ANOVA with
interaction effect between brain areas and groups was used
to compare HIV vDNA+ cell numbers. While the interaction
effect between brain areas and groups was significant (p =
0.0248), we performed a post-hoc analysis using Tukey test.
The means of HIV vDNA+ cell numbers were compared be-
tween groups within each brain area as depicted in Fig. 2.
Virally suppressed subjects with or without HAND had sig-
nificantly fewer HIV vDNA+ cells in the FWM compared to
the subjects with HIVE (Fig. 2a; p < 0.0001). However, no
statistically significant difference in the number of HIV
vDNA+ cells in the BG was found across the groups
(Fig. 2b, all p-values >0.3). Likewise, in CC, virally
Fig. 2 Comparison of vDNA levels between HIV-infected groups by
brain area. We compared the distribution of viral DNA (vDNA) in three
groups (G2 HIVE, G3 HAND, and G4 No HAND) through a two-way
ANOVA with Tukey multiple comparison test. a shows frontal white
matter (FWM), b basal ganglia (BG), and c corpus callosum (CC)
DNA. HIVE: human immunodeficiency virus encephalitis; HAND;
HIV-associated neurocognitive disorders
Fig. 3 Correlation of Global Deficit Score (GDS) to HIV vDNA in vi-
rally suppressed groups G3 and G4. a G3 (HAND) group, and b G4 (No
HAND) group. The slopes were not statistically significant except for one
slope with CC in G3 (a; r = 0.9059, p = 0.0129)
suppressed subjects with HAND had no significant difference
in the number of HIV vDNA+ cells compared to the subjects
with HIVE, although virally suppressed subjects with no
HAND had significantly fewer HIV vDNA+ cells than
those with HIVE (Fig. 2c; p < 0.001).
While there was no difference in the number of vDNA+
cells between virally suppressed patients with HAND and
those without HAND, we sought to investigate the relation-
ship between HIVDNA levels and global deficit score (GDS).
When we examined the relationship between the number of
vDNA+ cells in specific brain regions and GDS among virally
suppressed subjects, we found that there was a strong positive
correlation between the number of HIV vDNA+ cells in the
CC and GDS among virally suppressed subjects with HAND
(Fig. 3; r = 0.906, p = 0.0129). This suggests that the presence
of HIV-1 DNA in the brain, specific to particular regions in-
cluding corpus callosum, may be important in inducing
neurocognitive impairment.
We next examined HIV vRNA in all three brain regions of
all individuals from the three HIV-infected groups, including
those who were virally suppressed. Abundant HIV RNAwas
readily detected in all the brain regions from HIVE group
(Supplementary Fig. 1). We can distinguish cell-free vRNA
(virion, Fig. S1b, black arrowheads) from cell-associated
vRNA using the single-copy sensitive RNAscope ISH. As
shown in Fig. S1, vRNA in the brains of HIVE group exists
mainly in cell-associated form around small blood vessels.We
did not detect any in situ signals in the subjects from negative
control group using HIV-1 sense or antisense probes, and we
also did not detect any in situ signals from the subjects of
HIVE group using negative control probe (data not shown).
In the majority of the virally suppressed aviremic subjects, we
did not detect vRNA signals. However, we detected small
clusters of isolated vRNA signals, which were infrequent
and very focal, in 3 of 8 individuals from HAND group
(01986, 00006, 00009) and 3 of 8 individuals from No
HAND group (00658, 01878, 02087) (Fig. 4). Of note,
vRNA signals morphologically appear as discrete red puncta
representing cell-free virions (Fig. 4b& d, arrowheads), which
differ from vRNA signals in HIVE group where abundant
HIV vRNA signals were readily apparent in all the brain re-
gions (Fig. S1) and the entire cytoplasm of the infected cells
was filled with strong red puncta making individual puncta
impossible to discriminate (Fig. S1b).
Fig. 4 Small clusters of isolated vRNA signals were detected in the brain
tissues of six HIV-1 suppressed aviremic individuals fromHAND and No
HAND groups using RNAscope ISH. HIV-1 RNA signals morphologi-
cally appear as cell-free virions (discrete red puncta, arrows). a low mag-
nification of FWM and CC tissues from individual 00009 from HAND
group, and bmagnified image from the inset in the panel a, in which cell-
free virion derived signals (discrete red dots) were visible; c low magni-
fication of FWM and CC tissues from individual 01878 from the No
HAND group, and d magnified image from the inset in the panel c, in
which cell-free virion derived signals (discrete red dots) were visible
Next, we sought to determine the cellular phenotype of
vDNA+ cells in the brain, using DNAscope ISH in combina-
tion with IHC for CD68 (activated microglia/macrophages),
CD206 (PVM) and GFAP (astrocytes). In the brain of virally
suppressed subjects, HIV vDNA+ cells were found to be ei-
ther CD68+ (Fig. 5a) or CD206+ (Fig. 5b), but not GFAP+
(Fig. 6a). Interestingly, many if not all vDNA+ cells are locat-
ed around the vessels, suggesting, with their CD206 immuno-
reactivity, that they are PVM (Fabriek et al. 2005; Vogel et al.
2013; Holder et al. 2014). After we individually examined a
minimum of 40 vDNA+ cells each from virally suppressed
cases, we were not able to find any single vDNA+GFAP+
cells. In HIVE, cells harboring vDNA are also exclusively
CD68+ microglia/macrophages (data not shown). We also
examined the type of cells harboring vRNA in viremic sub-
jects from the HIVE group, vRNA+ cells were exclusively
colocalized with CD68 and CD206 (Supplementary Fig. 2a-
f, black arrows). We found no evidence of the presence of
vRNA in GFAP+ astrocytes in the brain with HIVE (Fig. 6b).
Recently, we demonstrated that a myeloid-specific host re-
striction factor SAMHD1 protein is upregulated and phos-
phorylated in the brain during SIV infection and correlates
with levels of brain SIV DNA (Lindgren et al. 2018). In the
current study, we examined SAMHD1 protein expression in
the brain of HIV patients with HIVE and virally suppressed
patients with or without HAND. There was a significant pos-
itive correlation between the number of SAMHD1+ nuclei
and the number of HIV vDNA+ cells in the FWM (r =
0.5401, p = 0.0096) and BG (r = 0.6609, p = 0.0006) although
we found no correlation in the CC (Supplementary Fig. 3).
Discussion
Previously, using a simian immunodeficiency virus (SIV)-in-
fected macaque model of HIV infection, Clements and col-
leagues showed that SIV DNA remained detectable in brain
after HAART although viral replication in the brain and CSF
Fig. 5 Representative images of
HIV-1 DNA+ macrophages in the
brain tissues from HIV infected
virally suppressed aviremic indi-
viduals. HIV-1 DNA+ cell types
were determined using
DNAscope ISH (a & c, vDNA,
red dot) in combination with IHC
for a cell-type marker (b CD68 or
d CD206). After being counter-
stained with hematoxylin, tissue
sections were digitized, and a
single channel image of vRNA
(red) and cell-type marker
(brown) were taken using
Aperio’s Spectrum Plus analysis
program. a, b vDNA and CD68
colocalization was indicated by
black arrows, BG tissue from in-
dividual 00009, c, d vDNA and
CD206 colocalization was indi-
cated by black arrows, FWM tis-
sue from individual 00719
was suppressed (Zink et al. 2010). A few brain studies exam-
ined the presence of HIV DNA by qPCR in the brains of HIV-
infected, ART-treated subjects (Gelman et al. 2013; Lamers
et al. 2016). However, it remains to be demonstrated which
cell type(s) harbors HIV DNA and/or RNA in the brain of
HIV patients receiving HAART that suppresses plasma viral
load to undetectable levels (Bvirally suppressed patients^).
The paucity of postmortem brain tissue from those who
achieved viral suppression has hindered such investigations.
In the present study, we are able show that cells harboring
HIV-1 DNA persist in the brain despite suppressive ART
and that these cells are exclusively macrophages/microglia.
Moreover, we found the presence of low-level HIV-1 RNA
in focal brain areas in a minority of virally suppressed patients,
suggesting either spontaneous viral reactivation or ongoing
low level replication despite suppressive ART. Notably, the
detected vRNA morphologically resembles cell-free virions,
which can infect adjacent cells to replenish reservoir. This is
the first formal demonstration that HIV-1 RNA can be
expressed in brains of virally suppressed patients. Therefore,
the present manuscript demonstrates brain macrophages as a
potential target for anti-HIV therapy. While our manuscript
was under revisions, Tso et al. (2018) also reported that sub-
type C HIV-1 was detected by droplet digital PCR in the
brains of two of four virally suppressed cases. They also dem-
onstrated colocalization of HIV vDNA with CD68+
macrophages/microglia in one virally suppressed case by
combined DNAscope ISH and IHC (Tso et al. 2018).
Interestingly, we found no evidence of the presence of
vDNA or vRNA in GFAP+ astrocytes in the brain of
aviremic or viremic HIV-infected patients. The role of
astrocytes as an HIV reservoir remains very controversial
with a few recent studies demonstrating the association of
HIV-1 DNA with astrocytes (as well as neurons, in one
study) using laser capture microdissection (LCM) (Trillo-
Pazos et al. 2003; Churchill et al. 2009; Thompson et al.
2011). Trillo-Pazos et al. detected the presence of HIV-1
gag DNA in pooled samples of 100 astrocytes from the
frontal cortical tissues of a pediatric and an adult AIDS
case. Likewise, Thompson et al. detected HIV-1 gag DNA
in 11 to 17% and 0 to 23% astrocytes in occipital regions
of HIVE and HIV cases, respectively. However, whether
astrocytes are infected remains to be proven as reactive
astrocytes serving as phagocytes has been recently sug-
gested. Churchill et al. have shown increased presence
of HIV DNA in LCM-isolated astrocytes when sub-
analyzed in association to proximity to PVM in AIDS
cases. Furthermore, a recent study using cultured human
fetal astrocytes suggests that HIV-1 DNA in astrocytes
occurs by uptake of HIV-1-infected debris by cell-cell
interaction with macrophages (Russell et al. 2017).
Alternatively, the close spatial proximity of HIV-infected
macrophages/microglia may serve as a source of contam-
ination in examination of astrocytes. In the current study,
however, we have not identified the presence of HIV-1
DNA or RNA, using single-copy sensitive RNAscope
and DNAscope, respectively, in GFAP+ astrocytes in the
brain of aviremic or viremic patients, which challenges
the findings of HIV-1 DNA in astrocytes seen in these
studies. Interestingly, in vitro studies on HIV infection
of astrocytes have shown that once a block to HIV fusion
and entry is artificially bypassed, there was no post-entry
restriction to HIV-1 replication (Canki et al. 2001; Russell
et al. 2017). The lack of intracellular restriction evolved in
human primary astrocytes indicates no virus-driven selec-
tion in this cell type during primate evolution.
When comparing the three HIV groups, we noticed a trend
of increased frequency of HIV-1 vDNA+ cells, specifically in
the CC, from virally suppressed subjects without HAND, to
Fig. 6 Representative images of HIV-1 vDNA and vRNA not
colocalizing with astrocytes in the brain tissues of HIV-infected aviremic
individuals on ART and viremic HIVE subjects respectively. a vDNA
(red) and GFAP (brown) showed no colocalization, which was indicated
by red arrows, FWM tissue from virally suppressed individual 01495. b
vRNA (red) and GFAP (green) showed no colocalization FWM tissue
from HIV-infected viremic HIVE individual 02390
subjects with HAND, and to subjects with HIVE. The above
findings along with the observation of a strong positive corre-
lation between HIV vDNA+ cells in the CC and GDS in virally
suppressed subjects with HANDmay suggest a potential role of
HIV in the brain in the development of neurocognitive impair-
ments despite suppressive long-term HAART. Brain imaging
studies of HAART treated HIV patients have previously shown
selective white matter disease (Garvey et al. 2014; Ragin et al.
2015; Randall et al. 2017; Buyukturkoglu et al. 2018) and a
correlation between loss of CC integrity with neurocognitive
deficits (Wu et al. 2006; Kelly et al. 2014). However, it is still
unclear whether the neurocognitive impairment in the era of
HAART is due to ART neurotoxicity or HIV induced
neuroinflammatory responses.
In summary, this study has identified for the first time the
persistence of HIV vDNA+ cells in the brain of virally sup-
pressed patients. Using DNAscope in situ hybridization tech-
nique, we found that HIV-1 DNA is harbored exclusively in
brain macrophages/microglia, especially PVM, but not astro-
cytes. Importantly, in a minority of virally suppressed
aviremic patients, isolated and focal vRNA was detected, in-
dicating there was a spontaneous viral reactivation and/or an
ongoing low-level focal replication despite suppressive ART.
Taken together, our findings suggest that brain macrophages
are a important HIV reservoir.
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